Weekly Analysts’ Ratings Changes for Alto Neuroscience (ANRO)

Alto Neuroscience (NYSE: ANRO) recently received a number of ratings updates from brokerages and research firms:

• 8/1/2026 – Alto Neuroscience was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 7/29/2026 – Alto Neuroscience had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/22/2026 – Alto Neuroscience was downgraded by Zacks Research from “hold” to “strong sell”.
• 7/18/2026 – Alto Neuroscience was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 6/17/2026 – Alto Neuroscience had its “buy” rating reaffirmed by HC Wainwright.

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.